Literature DB >> 1859471

Glutathione transferase mu deficiency is not a marker for predisposition to sulphonamide toxicity.

R J Riley1, A E Cribb, S P Spielberg.   

Abstract

Glutathione transferase mu activity, a marker for susceptibility to lung cancer and chemically induced cytogenetic damage, is not a predictive index for the predisposition to sulphonamide hypersensitivity reactions. However, considering the functional diversity and broad, overlapping substrate specificity of GSH-dependent enzymes, it is conceivable that an as yet unidentified deficiency in another GST isozyme or GSH-related enzyme may be a marker for sulphonamide toxicity. In addition, heterogeneity in cellular repair mechanisms and the diversity of the human immune response [22] may also contribute to the manifestation of the toxic effects of sulphonamides. Experiments are currently in progress to determine which of this myriad of variables is predominantly responsible for inter-individual susceptibility to the idiosyncratic reactions produced by these antibacterial agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1859471     DOI: 10.1016/0006-2952(91)90334-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.

Authors:  S P Spielberg
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

Review 2.  Idiosyncratic drug reactions: a mechanistic evaluation of risk factors.

Authors:  B K Park; M Pirmohamed; N R Kitteringham
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

Review 3.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

4.  Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis.

Authors:  V J Green; M Pirmohamed; N R Kitteringham; M J Knapp; B K Park
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

Review 5.  In vitro analysis of metabolic predisposition to drug hypersensitivity reactions.

Authors:  R J Riley; J S Leeder
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

6.  RNA expression profiling in sulfamethoxazole-treated patients with a range of in vitro lymphocyte cytotoxicity phenotypes.

Authors:  Jennifer M Reinhart; Warren Rose; Daniel J Panyard; Michael A Newton; Tyler K Liebenstein; Jeremiah Yee; Lauren A Trepanier
Journal:  Pharmacol Res Perspect       Date:  2018-03-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.